1. Home
  2. UVE vs OMER Comparison

UVE vs OMER Comparison

Compare UVE & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVE
  • OMER
  • Stock Information
  • Founded
  • UVE 1990
  • OMER 1994
  • Country
  • UVE United States
  • OMER United States
  • Employees
  • UVE N/A
  • OMER N/A
  • Industry
  • UVE Property-Casualty Insurers
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • UVE Finance
  • OMER Health Care
  • Exchange
  • UVE Nasdaq
  • OMER Nasdaq
  • Market Cap
  • UVE 585.8M
  • OMER 667.0M
  • IPO Year
  • UVE 1992
  • OMER 2009
  • Fundamental
  • Price
  • UVE $20.65
  • OMER $10.31
  • Analyst Decision
  • UVE Buy
  • OMER Buy
  • Analyst Count
  • UVE 1
  • OMER 3
  • Target Price
  • UVE $25.00
  • OMER $9.00
  • AVG Volume (30 Days)
  • UVE 144.4K
  • OMER 1.4M
  • Earning Date
  • UVE 02-20-2025
  • OMER 11-13-2024
  • Dividend Yield
  • UVE 3.10%
  • OMER N/A
  • EPS Growth
  • UVE 4.62
  • OMER N/A
  • EPS
  • UVE 2.48
  • OMER N/A
  • Revenue
  • UVE $1,511,183,000.00
  • OMER N/A
  • Revenue This Year
  • UVE N/A
  • OMER N/A
  • Revenue Next Year
  • UVE N/A
  • OMER N/A
  • P/E Ratio
  • UVE $8.31
  • OMER N/A
  • Revenue Growth
  • UVE 12.23
  • OMER N/A
  • 52 Week Low
  • UVE $15.78
  • OMER $2.61
  • 52 Week High
  • UVE $23.39
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • UVE 36.91
  • OMER 58.84
  • Support Level
  • UVE $21.09
  • OMER $7.20
  • Resistance Level
  • UVE $21.52
  • OMER $13.60
  • Average True Range (ATR)
  • UVE 0.57
  • OMER 1.38
  • MACD
  • UVE -0.22
  • OMER -0.30
  • Stochastic Oscillator
  • UVE 22.02
  • OMER 48.59

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums. It operates within Florida and across the United States. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: